Russia’s Sputnik V Covid-19 vaccine has proven to be highly effective and safe in the age group from 12 to 17 during clinical trials, one of its leading developers has told RT.
The phase one and two clinical trials enabled a safe dosage of the formula to be determined for teens, which is 1/5 of the adult dose, Denis Logunov, the deputy head of the Moscow-based Gamaleya Institute which developed the Sputnik V, explained, in a segment broadcast on Wednesday.
Continue reading https://on.rt.com/bll2